Abstract
This review focuses on the mechanisms of action and the injurious effect of complex I inhibitors, of which 1-methyl-4-phenylpyridinium ion (MPP+) is a well studied example. These compounds can be divided into two groups, i.e. competitive inhibitors with respect to ubiquinone, such as piericidine A, and noncompetitive inhibitors such as rotenone. Complex I inhibitors such as MPP+ have been reported to induce anatomical, behavioral, and biochemical changes similar to those seen in Parkinsons disease, which is characterized by nigrostriatal dopaminergic neuro-degeneration. Spectroscopic analyses and structure-activity relationship studies have indicated that the V-shaped structure of the rotenone molecule is critical for binding to the rotenone binding site on complex I. Many isoquinoline derivatives, some of them endogenous, are also complex I inhibitors. Many lines of evidence show that complex I inhibitors elicit neuronal cell death. Recently, it was reported that chronic and systemic exposure to low-dose rotenone reproduces the features of Parkinsons disease. This work further focused attention on compounds acting on mitochondria, such as MPP+. In Guadeloupe, the French West Indies, patients with atypical parkinsonism or progressive supranuclear palsy are frequently encountered. These diseases seem to be associated with ingestion of tropical herbal teas or tropical fruits of the Annonaceae family, which contain complex I inhibitors such as benzylisoquinoline derivatives and acetogenins. Complex I inhibitors may not simply result in reactive oxygen species generation or ATP exhaustion, but may influence complex downstream signal transduction processes. An understanding of these changes would throw light on the ways in which complex I inhibitors induce a wide range of abnormalities.
Keywords: complex I inhibitor, parkinson's disease, rotenone, apoptosis, tetrahydroisoquinoline, benzylisoquinoline alkaloid, acetogenin
Current Medicinal Chemistry
Title: MPP+ Analogs Acting on Mitochondria and Inducing Neuro-Degeneration
Volume: 10 Issue: 23
Author(s): Y. Kotake and S. Ohta
Affiliation:
Keywords: complex I inhibitor, parkinson's disease, rotenone, apoptosis, tetrahydroisoquinoline, benzylisoquinoline alkaloid, acetogenin
Abstract: This review focuses on the mechanisms of action and the injurious effect of complex I inhibitors, of which 1-methyl-4-phenylpyridinium ion (MPP+) is a well studied example. These compounds can be divided into two groups, i.e. competitive inhibitors with respect to ubiquinone, such as piericidine A, and noncompetitive inhibitors such as rotenone. Complex I inhibitors such as MPP+ have been reported to induce anatomical, behavioral, and biochemical changes similar to those seen in Parkinsons disease, which is characterized by nigrostriatal dopaminergic neuro-degeneration. Spectroscopic analyses and structure-activity relationship studies have indicated that the V-shaped structure of the rotenone molecule is critical for binding to the rotenone binding site on complex I. Many isoquinoline derivatives, some of them endogenous, are also complex I inhibitors. Many lines of evidence show that complex I inhibitors elicit neuronal cell death. Recently, it was reported that chronic and systemic exposure to low-dose rotenone reproduces the features of Parkinsons disease. This work further focused attention on compounds acting on mitochondria, such as MPP+. In Guadeloupe, the French West Indies, patients with atypical parkinsonism or progressive supranuclear palsy are frequently encountered. These diseases seem to be associated with ingestion of tropical herbal teas or tropical fruits of the Annonaceae family, which contain complex I inhibitors such as benzylisoquinoline derivatives and acetogenins. Complex I inhibitors may not simply result in reactive oxygen species generation or ATP exhaustion, but may influence complex downstream signal transduction processes. An understanding of these changes would throw light on the ways in which complex I inhibitors induce a wide range of abnormalities.
Export Options
About this article
Cite this article as:
Kotake Y. and Ohta S., MPP+ Analogs Acting on Mitochondria and Inducing Neuro-Degeneration, Current Medicinal Chemistry 2003; 10 (23) . https://dx.doi.org/10.2174/0929867033456558
DOI https://dx.doi.org/10.2174/0929867033456558 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Voltammetric Analysis of Atypical Antipsychotic Drugs with Solid Electrodes
Current Analytical Chemistry Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Neuroscience and Biomedical Engineering (Discontinued) Undesired Neural Side-Effects of a Drug, a Chemical and Genetic Interrelated Problem
Central Nervous System Agents in Medicinal Chemistry Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men
Current Alzheimer Research Differences Between COPD Patients of a Pulmonary Rehabilitation Program According to the mMRC Dyspnea Scale
Current Respiratory Medicine Reviews The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Clinical Observation of Electroencephalographic Changes and Risk of Convulsion Occurrence in Children Receiving Neural Precursor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Molecular Approaches for Neuropathic Pain Treatment
Current Medicinal Chemistry Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Current Drug Targets - Inflammation & Allergy Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction
CNS & Neurological Disorders - Drug Targets Synthesis and Pharmacological Studies of Novel 3-Substituted Indole Derivatives as Potential Anti-Inflammatory and Analgesic Agents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Treatment of Postpartum Psychosis: Challenges and Opportunities
Current Drug Safety Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Functional Consequences of Locus Coeruleus Degeneration in Alzheimers Disease
Current Alzheimer Research Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design